ClinicalTrials.gg

Program

bexobrutideg

Its studies are mostly in Lymphoma, B-Cell · Leukemia, Lymphocytic, Chronic, B-Cell, led by Nurix Therapeutics.

Furthest: phase 3, since Mar 31, 20266 company-led studies, 4 open or runningNext primary completion: Jan 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nurix Therapeutics64 open or runningphase 3since Mar 31, 2026Nov 12, 2021Jan 2027phase 1 · NCT05131022
  • Named in hoffmann la roche’s own pipeline as RG7473 bexobrutideg (Nurix), phase 3, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 12, 2021First study: phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT05131022 · 572 planned · United States, France, Italy and more
  2. Nov 1, 2024Phase 1 study in Healthy VolunteerNCT06691828 · 8 enrolled · United States
  3. Dec 1, 2024Phase 1 study in Healthy VolunteerNCT06717269 · 223 enrolled · United States
  4. Oct 24, 2025Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07221500 · 100 planned · United States, France, Italy and more
  5. Mar 31, 2026Phase 3 study in Lymphoma, B-CellPhase 3 reachedNCT07516093 · 620 planned · United States
  6. Apr 2, 2026Phase 2 study in Lymphoma, B-CellNCT07520006 · 150 planned · United States

Ahead

  1. Jan 2027Primary completion: phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05131022
  2. Jan 2028Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07221500
  3. Oct 2029Primary completion: phase 3 study in Lymphoma, B-CellNCT07516093
  4. May 2033Primary completion: phase 2 study in Lymphoma, B-CellNCT07520006

TargetBeta

BTK →HSF4 →read by rule
“An orally bioavailable chimeric targeting molecule (CTM) and targeted degrader of Bruton's tyrosine kinase (BTK), ”NCIt, by rule

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07520006Lymphoma, B-Cell · United States2RecruitingMay 2033150
NCT07516093Lymphoma, B-Cell · United States3RecruitingOct 2029620
NCT07221500Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Italy and more2RecruitingJan 2028100
NCT06717269Healthy Volunteer · United States1CompletedMay 1, 2026223
NCT06691828Healthy Volunteer · United States1CompletedNov 28, 20248
NCT05131022Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Italy and more1RecruitingJan 2027572

How it is read

Names in the registry

  • “NX-5948”, 7 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.